Does the media prefer CRSP or MRNA?

In the previous week, Moderna had 18 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 33 mentions for Moderna and 15 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.68 beat Moderna's score of 0.40 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to MRNA or HOOD?

In the previous week, Robinhood Markets had 25 more articles in the media than Moderna. MarketBeat recorded 58 mentions for Robinhood Markets and 33 mentions for Moderna. Robinhood Markets' average media sentiment score of 0.53 beat Moderna's score of 0.40 indicating that Robinhood Markets is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Robinhood Markets 26 Very Positive mention(s) 8 Positive mention(s) 15 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NVAX or MRNA?

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.48 $440.30M -$1.52 N/A Moderna $1.94B 31.63 -$2.82B -$7.99 N/A

Is NVAX or MRNA more profitable?

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Moderna -141.43% -28.30% -19.39%

Does the media prefer NVAX or MRNA?

In the previous week, Moderna had 22 more articles in the media than Novavax. MarketBeat recorded 33 mentions for Moderna and 11 mentions for Novavax. Novavax's average media sentiment score of 0.66 beat Moderna's score of 0.40 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 81.51 -$67.85M -$0.26 N/A Moderna $1.94B 31.63 -$2.82B -$7.99 N/A

Is OCGN or MRNA more profitable?

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Moderna -141.43% -28.30% -19.39%

Does the media prefer OCGN or MRNA?

In the previous week, Moderna had 29 more articles in the media than Ocugen. MarketBeat recorded 33 mentions for Moderna and 4 mentions for Ocugen. Moderna's average media sentiment score of 0.40 beat Ocugen's score of -0.12 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to MRNA or REGN?

In the previous week, Moderna had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 33 mentions for Moderna and 22 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.56 beat Moderna's score of 0.40 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Moderna (MRNA) Competitors

$154.03 -4.04 (-2.56%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$153.90 -0.13 (-0.09%)

As of 09/18/2026 07:59 PM Eastern

Compare

MRNA vs. CRSP, HOOD, NVAX, OCGN, and REGN

Should you buy Moderna stock or one of its competitors? Moderna's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), and Regeneron Pharmaceuticals (REGN). Companies are selected based on similarities in market, industry, and size.

How does Moderna compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

CRISPR Therapeutics presently has a consensus target price of $67.94, indicating a potential upside of 20.12%. Moderna has a consensus target price of $76.72, indicating a potential downside of 50.19%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe CRISPR Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.59
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Moderna has a net margin of -141.43% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Moderna	-141.43%	-28.30%	-19.39%

CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

In the previous week, Moderna had 18 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 33 mentions for Moderna and 15 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.68 beat Moderna's score of 0.40 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,558.06	-$581.60M	-$4.76	N/A
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A

Summary

CRISPR Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Moderna compare to Robinhood Markets?

Moderna (NASDAQ:MRNA) and Robinhood Markets (NASDAQ:HOOD) are related large-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Robinhood Markets has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Robinhood Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A
Robinhood Markets	$4.47B	24.08	$1.88B	$2.27	52.78

75.3% of Moderna shares are held by institutional investors. Comparatively, 93.3% of Robinhood Markets shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 13.5% of Robinhood Markets shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Robinhood Markets has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

Moderna currently has a consensus target price of $76.72, indicating a potential downside of 50.19%. Robinhood Markets has a consensus target price of $130.88, indicating a potential upside of 9.23%. Given Robinhood Markets' stronger consensus rating and higher possible upside, analysts plainly believe Robinhood Markets is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Robinhood Markets	0 Sell rating(s)	3 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.96

Robinhood Markets has a net margin of 42.01% compared to Moderna's net margin of -141.43%. Robinhood Markets' return on equity of 22.43% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Robinhood Markets	42.01%	22.43%	4.56%

In the previous week, Robinhood Markets had 25 more articles in the media than Moderna. MarketBeat recorded 58 mentions for Robinhood Markets and 33 mentions for Moderna. Robinhood Markets' average media sentiment score of 0.53 beat Moderna's score of 0.40 indicating that Robinhood Markets is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Robinhood Markets	26 Very Positive mention(s)	8 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Robinhood Markets beats Moderna on 16 of the 17 factors compared between the two stocks.

How does Moderna compare to Novavax?

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novavax presently has a consensus target price of $14.00, indicating a potential upside of 38.48%. Moderna has a consensus target price of $76.72, indicating a potential downside of 50.19%. Given Novavax's stronger consensus rating and higher probable upside, equities research analysts plainly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Moderna	-141.43%	-28.30%	-19.39%

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.48	$440.30M	-$1.52	N/A
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 22 more articles in the media than Novavax. MarketBeat recorded 33 mentions for Moderna and 11 mentions for Novavax. Novavax's average media sentiment score of 0.66 beat Moderna's score of 0.40 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Novavax beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Moderna compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Moderna	-141.43%	-28.30%	-19.39%

In the previous week, Moderna had 29 more articles in the media than Ocugen. MarketBeat recorded 33 mentions for Moderna and 4 mentions for Ocugen. Moderna's average media sentiment score of 0.40 beat Ocugen's score of -0.12 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	81.51	-$67.85M	-$0.26	N/A
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 796.23%. Moderna has a consensus price target of $76.72, suggesting a potential downside of 50.19%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts plainly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Ocugen has a beta of 2.2, indicating that its stock price is 120% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Summary

Ocugen and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Moderna compare to Regeneron Pharmaceuticals?

Moderna (NASDAQ:MRNA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Moderna presently has a consensus price target of $76.72, suggesting a potential downside of 50.19%. Regeneron Pharmaceuticals has a consensus price target of $802.18, suggesting a potential upside of 2.21%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A
Regeneron Pharmaceuticals	$14.34B	5.63	$4.50B	$40.46	19.40

In the previous week, Moderna had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 33 mentions for Moderna and 22 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.56 beat Moderna's score of 0.40 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Moderna has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Moderna on 12 of the 16 factors compared between the two stocks.

Get Moderna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRNA vs. The Competition

Export

Metric	Moderna	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.11B	$3.92B	$7.26B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-19.28	14.30	275.79	25.40
Price / Sales	31.63	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	6.96	15.45	10.46	6.33
Net Income	-$2.82B	-$22.86M	$3.49B	$358.33M
7 Day Performance	6.99%	-1.21%	0.59%	1.12%
1 Month Performance	-11.67%	-4.42%	-2.01%	-2.67%
1 Year Performance	510.27%	37.81%	18.09%	6.01%

Moderna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRNA Moderna	2.1596 of 5 stars	$154.03 -2.6%	$76.72 -50.2%	+505.2%	$63.11B	$1.94B	N/A	4,700	Trending News Insider Trade
CRSP CRISPR Therapeutics	2.4144 of 5 stars	$53.10 +2.7%	$68.06 +28.2%	-10.1%	$5.15B	$3.51M	N/A	393
HOOD Robinhood Markets	3.6736 of 5 stars	$114.51 +1.7%	$129.83 +13.4%	-0.9%	$102.74B	$4.47B	50.34	2,900	Trending News Analyst Forecast Insider Trade Options Volume Gap Up
NVAX Novavax	2.5319 of 5 stars	$9.45 +0.3%	$14.00 +48.2%	+18.5%	$1.56B	$1.12B	N/A	749
OCGN Ocugen	1.7151 of 5 stars	$1.06 +3.4%	$9.50 +800.5%	-24.3%	$357.76M	$4.41M	N/A	116

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRNA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Competitors

MRNA vs. CRSP, HOOD, NVAX, OCGN, and REGN

How does Moderna compare to CRISPR Therapeutics?

Summary

How does Moderna compare to Robinhood Markets?

Summary

How does Moderna compare to Novavax?

Summary

How does Moderna compare to Ocugen?

Summary

How does Moderna compare to Regeneron Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA vs. The Competition

Moderna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moderna (MRNA) Competitors

MRNA vs. CRSP, HOOD, NVAX, OCGN, and REGN

How does Moderna compare to CRISPR Therapeutics?

Do analysts rate CRSP or MRNA?

Is CRSP or MRNA more profitable?

Which has more volatility & risk, CRSP or MRNA?

Does the media prefer CRSP or MRNA?

Do insiders & institutionals believe in CRSP or MRNA?

Which has preferable valuation and earnings, CRSP or MRNA?

Summary

How does Moderna compare to Robinhood Markets?

Which has stronger earnings & valuation, MRNA or HOOD?

Do institutionals & insiders hold more shares of MRNA or HOOD?

Which has more risk & volatility, MRNA or HOOD?

Do analysts rate MRNA or HOOD?

Is MRNA or HOOD more profitable?

Does the media refer more to MRNA or HOOD?

Summary

How does Moderna compare to Novavax?

Which has more volatility and risk, NVAX or MRNA?

Do institutionals & insiders believe in NVAX or MRNA?

Do analysts recommend NVAX or MRNA?

Is NVAX or MRNA more profitable?

Which has better earnings and valuation, NVAX or MRNA?

Does the media prefer NVAX or MRNA?

Summary

How does Moderna compare to Ocugen?

Is OCGN or MRNA more profitable?

Does the media prefer OCGN or MRNA?

Do insiders and institutionals have more ownership in OCGN or MRNA?

Which has higher earnings & valuation, OCGN or MRNA?

Do analysts rate OCGN or MRNA?

Which has more volatility and risk, OCGN or MRNA?

Summary

How does Moderna compare to Regeneron Pharmaceuticals?

Do analysts recommend MRNA or REGN?

Which has higher earnings & valuation, MRNA or REGN?

Does the media refer more to MRNA or REGN?

Is MRNA or REGN more profitable?

Which has more risk & volatility, MRNA or REGN?

Do insiders & institutionals have more ownership in MRNA or REGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA vs. The Competition

Moderna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools